The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1459
January 5, 2015
View Complete Issue         Table of Contents 2019 
Olodaterol (Striverdi Respimat) for COPD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Olodaterol (Striverdi Respimat) for COPD
January 5, 2015 (Issue: 1459)
Olodaterol (Striverdi Respimat – Boehringer Ingelheim), a new inhaled long-acting beta2-agonist, has been approved by the FDA for once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Olodaterol (Striverdi Respimat) for COPD
Article code: 1459b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.